Julie Casoetto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julie Casoetto has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alain Dumont
Department of Anaesthesiology and Intensive Care Medicine, Centre Hospitalier Universitaire, Avenue A Raymond, Saint Etienne, 42055, France
1 shared publication - Christian Auboyer
Département d'anesthésie réanimation, Centre Hospitalier Universitaire de Saint Etienne, 42055 Saint Etienne cedex 02, France
1 shared publication - Gerald Aubert
Laboratory of Antibiology, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
1 shared publication - Jerome Morel
Laboratoire Interuniversitaire de Biologie de la Motricité Université Jean Monnet Saint Etienne, Lyon 1, Université Savoie Mont‐Blanc Saint Etienne France
1 shared publication - Raphael Terrana
Department of Anaesthesiology and Intensive Care Medicine, Centre Hospitalier Universitaire, Avenue A Raymond, Saint Etienne, 42055, France
1 shared publication - Richard Jospé
Department of Anaesthesiology and Intensive Care Medicine, Centre Hospitalier Universitaire, Avenue A Raymond, Saint Etienne, 42055, France
1 shared publication
Latest Publications
- Open Access
- 17 December 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (6) , R225
De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit
Introduction: Most data on de-escalation of empirical antimicrobial therapy has focused on ventilator-associated pneumonia. In this retrospective monocentric study, we evaluated de-escalation as part of a global strategy of empiric antibiotherapy management irrespective of the location and the severity of the infection. The goal of this trial was to assess the application of a de-escalation strategy and the impact in terms of re-escalation, recurrent infection and to identify variables associated with de-escalation. Methods: All consecutive patients treated with empiric antibiotic therapy and hospitalized in the intensive care unit for at least 72 hours within a period of 16 months were included. We compared the characteristics and outcome of patients who have experienced de-escalation therapy with those who have not. Results: A total of 116 patients were studied corresponding to 133 infections. Antibiotic therapy was de-escalated in 60 cases (45%). De-escalation, primarily accomplished by a reduction in the number of antibiotics used, was observed in 52% of severe sepsis or septic shock patients. Adequate empiric antibiotic and use of aminoglycoside were independently linked with de-escalation. De-escalation therapy was associated with a significant reduction of recurrent infection (19% vs 5% P = 0.01). Mortality was not changed by de-escalation. Conclusions: As part of a global management of empiric antibiotherapy in an intensive care unit, de-escalation might be safe and feasible in a large proportion of patients.
- 17 December 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (6) , R225
Open AccessDe-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit
Introduction: Most data on de-escalation of empirical antimicrobial therapy has focused on ventilator-associated pneumonia. In this retrospective monocentric study, we evaluated de-escalation as part of a global strategy of empiric antibiotherapy management irrespective of the location and the severity of the infection. The goal of this trial was to assess the application of a de-escalation strategy and the impact in terms of re-escalation, recurrent infection and to identify variables associated with de-escalation. Methods: All consecutive patients treated with empiric antibiotic therapy and hospitalized in the intensive care unit for at least 72 hours within a period of 16 months were included. We compared the characteristics and outcome of patients who have experienced de-escalation therapy with those who have not. Results: A total of 116 patients were studied corresponding to 133 infections. Antibiotic therapy was de-escalated in 60 cases (45%). De-escalation, primarily accomplished by a reduction in the number of antibiotics used, was observed in 52% of severe sepsis or septic shock patients. Adequate empiric antibiotic and use of aminoglycoside were independently linked with de-escalation. De-escalation therapy was associated with a significant reduction of recurrent infection (19% vs 5% P = 0.01). Mortality was not changed by de-escalation. Conclusions: As part of a global management of empiric antibiotherapy in an intensive care unit, de-escalation might be safe and feasible in a large proportion of patients.